

ODONTOPREV S.A.
Corporate Taxpayer's ID (CNPJ/MF) 58.119.199/0001-51
Corporate Registry ID (NIRE) 35.300.156.668
PUBLICLY HELD COMPANY

**MINUTES OF THE EXTRAORDINARY GENERAL MEETING
HELD ON APRIL 6TH, 2026**

DAY, TIME AND PLACE: Held on April 6, 2026, at 10:00 a.m. ("Meeting"), exclusively online via the ALFM Easy Voting electronic platform ("Platform"), and deemed to have taken place at the registered office of Odontoprev S.A. ("Company") located at Alameda Araguaia, No. 2104, 21st floor, Alphaville, ZIP Code 06455-000, in the city of Barueri, State of São Paulo, in accordance with CVM Resolution No. 81/2022 ("RCVM 81").

CALL NOTICE: The notice convening this Meeting was published on March 9, 10, and 11, 2026, in the newspaper Valor Econômico, on pages E6, E2, and E2, respectively (Only in Portuguese). The documents required by CVM Resolution No. 80/2022 ("RCVM 80") and RCVM 81 were also made available to the market electronically.

ATTENDANCE: Shareholders of the Company were present, representing approximately 76.16% of the voting capital, as evidenced by (i) the summary voting tally, consolidating the votes cast remotely, released on April 4, 2026, by the Company; and (ii) by the attendance records via the Platform, pursuant to Article 47, item III, of RCVM 81. Also present were Mr. Luiz Carlos Trabuco Cappi, Chairman of the Board of Directors; Mr. Ivan Luiz Gontijo Junior, Vice Chairman of the Board of Directors; and the other members of the Company's Board of Directors; Mr. Elsen Carvalho, in his capacity as Chief Executive Officer of the Company, and the other members of the Executive Board; the members of the Company's Fiscal Council; and Mr. Miguel Monteiro, representative of Apsis Consultoria e Avaliações Ltda.

INSTATEMENT: Chairman: Mr. Luiz Carlos Trabuco Cappi; Secretary: Andre Chidichimo França.

AGENDA: (i) To review, discuss, and approve the "Protocol and Justification for the Merger of Bradesco Gestão de Saúde S.A. into Odontoprev S.A.," as amended and consolidated ("Protocol and Justification"), which contains all the terms and conditions of the business combination involving the Company and Bradesco Gestão de Saúde S.A. ("BGS" and "Transaction," respectively), among which the merger of the shares issued by BGS into the Company ("Share Merger") stands out; (ii) to ratify the appointment of the specialized firm Apsis Consultoria e Avaliações Ltda., registered with the CNPJ/MF under No. 27.281.922/0001-70 ("Appraisal Firm" or

"Apsis"), as the entity responsible for preparing (a) the appraisal report on the shares issued by the Company, at fair market value, for the purpose of determining the redemption amount to be paid to dissenting shareholders of the Company who exercise their right of withdrawal as a result of the Share Merger, pursuant to Article 45, paragraphs 3 and 4, of Law No. 6,404/76 and Article 7, paragraph 3, of the Company's bylaws ("Recess Valuation Report"); (b) the appraisal report on the shares issued by BGS, at market value, for the purpose of determining the amount of Odontoprev's capital increase resulting from the Stock Merger, pursuant to Articles 8 and 252 of the Brazilian Corporations Law ("Valuation Report – Capital Increase"); and (c) the valuation report of the net equity at market prices of Odontoprev and BGS, for the purpose of comparing the exchange ratio relating to the Stock Merger, pursuant to Article 264 of the Brazilian Corporations Law ("Valuation Report 264" and, together with the Recess Valuation Report and the Valuation Report – Capital Increase, "Valuation Reports"); **(iii)** approve the Valuation Reports; **(iv)** approve the merger of shares, in accordance with the Protocol and Justification; **(v)** to approve the increase in the Company's capital stock resulting from the Stock Merger, and the consequent amendment to Article 6 of the Company's Bylaws; **(vi)** approve the amendment to the Company's bylaws and the resulting consolidation; **(vii)** approve, subject to the terms and conditions of the applicable regulations, the contribution of Odontoprev's dental plan portfolio and other operating assets and liabilities to Mediservice Operadora de Planos de Saúde S.A., which is, as of today, an indirect subsidiary of BGS ("Contribution of Assets"); and **(viii)** authorize the Company's management to perform any and all acts necessary for the implementation of the resolutions adopted at this meeting.

RESOLUTIONS: Following a review and discussion of the items on the agenda, the following resolutions were adopted, the effectiveness of which is subject to the fulfillment of the conditions precedent set forth in the Protocol and Justification:

(i) The following was reviewed, discussed, and approved by a majority vote of the shareholders present, with 380,527,490 votes in favor, 27,351,341 votes against, and 7,299,403 abstentions recorded: the Protocol and Justification, which was disclosed by the Company to the market electronically, pursuant to RCM 80 and RCM 81, as set forth in **Annex I** to these minutes.

(ii) The ratification of the appointment of the Appraisal Firm to prepare the Appraisal Reports was approved by a majority vote of the shareholders present, with 380,529,364 votes in favor, 27,376,916 votes against, and 7,271,954 abstentions recorded.

(iii) The Valuation Reports were approved by a majority vote of the shareholders present, with 379,677,786 votes in favor, 27,379,445 votes against, and 8,121,003 abstentions recorded. These reports were disclosed by the Company to the market electronically, pursuant to RCVM 80 and RCVM 81. The Recess Valuation Report is included in **Annex II** to these minutes, the Capital Increase Valuation Report is included in **Annex II to the Protocol and Justification**, and the Valuation Report 264 is included in **Annex III to the Protocol and Justification**.

(iv) The Stock Merger was approved by a majority vote of the shareholders present, with 380,523,687 votes in favor, 27,382,954 votes against, and 7,271,593 abstentions recorded.

(v) The increase in the Company's capital stock resulting from the Stock Merger, in the amount of R\$ 14,053,473,000.00 (fourteen billion, fifty-three million, four hundred seventy-three thousand reais), through the issuance of 2,378,374,445 (two billion, three hundred seventy-eight million, three hundred seventy-four thousand, four hundred forty-five) common shares, registered and without par value, subject, furthermore, to the adjustments provided for in the Protocol and Justification until the closing of the Transaction, as well as the allocation of the additional amount of R\$ 34,825,711,000.00 (thirty-four billion, eight hundred twenty-five million, seven hundred eleven thousand reais) for the establishment of a capital reserve, pursuant to Article 182, §1, "a," of the Brazilian Corporations Law. Consequently, the amendment to Article 6, caput, of the Company's bylaws was also approved by the same number of votes to reflect the capital increase, which shall now read as follows:

"Article 6 - *The Company's capital stock is R\$ 14,904,489,554.14 (fourteen billion, nine hundred and four million, four hundred and eighty-nine thousand, five hundred and fifty-four reais and fourteen centavos), fully subscribed and paid in, divided into 2,924,199,731 (two billion, nine hundred twenty-four million, one hundred ninety-nine thousand, seven hundred thirty-one) common shares, all registered, book-entry, and without par value."*

(vi) The amendment of the Company's bylaws and their subsequent consolidation were approved by a majority vote of the shareholders present, with 380,355,527 votes in favor, 27,527,457 votes against, and 7,295,250 abstentions recorded, with the following changes: (a) the change of the Company's corporate name to "Bradsaúde S.A.," through an amendment to Article 1 of the bylaws; (b) the amendment of the Company's corporate purpose, through a modification of the heading of Article 4 and the inclusion of paragraphs 1 and 2 of the bylaws, with provision for a transitional

regime to maintain operational activities, until the earlier of (1) the cancellation of the Company's registration as a health care plan operator with the National Supplementary Health Agency ("ANS"), which shall be the subject of a specific administrative proceeding with the ANS, or (2) the ANS's authorization to exclude the operation of private dental care plans from the bylaws; (c) updating the amount of the Company's capital stock and the number of shares into which the capital stock is divided, as a result of the Stock Merger, by amending Article 6 of the bylaws, in accordance with the resolution adopted in item (v) of the meeting's agenda; and (d) the inclusion of a new Article 42 in the bylaws, establishing certain amendments to the bylaws that will take effect upon the cancellation of the Company's registration as a health plan operator with the ANS, or as soon as the ANS authorizes such changes, whichever occurs first.

The amended and consolidated bylaws, as approved under this agenda item, shall take effect in accordance with **Annex III** to these minutes.

(vii) The following was approved by a majority vote of the shareholders present, with 380,522,708 votes in favor, 27,353,139 votes against, and 7,302,387 abstentions recorded: the Contribution of Assets, subject to the terms and conditions of applicable regulations, as well as the completion of the Share Merger hereby approved.

(viii) The authorization for the Company's management to take all necessary measures to implement the resolutions approved at the Meeting was approved by a majority vote of the shareholders present, with 380,561,094 votes in favor, 27,353,137 votes against, and 7,264,003 abstentions recorded.

EFFECTIVENESS OF THE RESOLUTIONS: It is hereby noted that the conditions precedent set forth in the Protocol and Justification have been duly verified, and BGS has also approved on this date all resolutions involving the Stock Merger, such that the effectiveness of the resolutions covered by items (iv) (Stock Merger), (v) (capital increase), and (vi) (change of corporate name, other amendments to the bylaws, and consolidation of the bylaws) above: (a) is subject solely to approval by the Boards of Directors of the Company and BGS, and (b) will take effect on April 30, 2026—without prejudice to the transitional provisions included in the bylaws, which shall remain in effect until the respective conditions precedent are satisfied, pursuant to item (vi) above –, as provided for in Clause 7.3.1 of the Protocol and Justification, and therefore even before the expiration of the deadline (and with the Company's Board of Directors waiving its right to reconsider the Transaction due to) the exercise of the right of withdrawal by its dissenting shareholders.

CLOSURE: As there were no further matters to discuss, and since none of those present wished to speak, the meeting was adjourned, and these minutes were drawn up in summary form, to be published without the signatures of the shareholders present, in accordance with the provisions of Article 130 of the Brazilian Corporations Law, and the respective Annexes, which are filed at the Company's headquarters. These minutes were read, found to be in order, and signed by a sufficient number of shareholders to validate them, pursuant to Article 130 of the Brazilian Corporations Law.

Barueri/SP, April 6th, 2026.

Instatement:

Luiz Carlos Trabuco Cappi
Chairman

André Chidichimo de França
Secretary